Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
Retrieved on:
Thursday, March 31, 2022
FDA, Health, Consumer, Women, Pharmaceutical, Biotechnology, MSD, Birth, Risk, BV, MRK, NASDAQ, Bacterial vaginosis, Sale, Patent, Investment, Gaps, Form, Forward-looking statement, Fertility, Growth, OGN, Merck & Co., Multimedia, NYSE, Health minister, Bacteria, SEC, QIDP, Woman, Health, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Industry, Review, Twitter, COVID-19, 8-K, Vaginitis, Hart–Scott–Rodino Antitrust Improvements Act, News, Annual report, FDA, Merck, Security (finance), Pharmaceutical industry, Birth control, Online shopping, Risk management, Organon, ORGANON, DARé BIOSCIENCE
XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
Key Points:
- XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
- XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.
- BV is the most common cause of vaginitis worldwide and is estimated to affect approximately 21 million women in the U.S.
- Sabrina Martucci Johnson, Dars President and Chief Executive Officer, commented, Organon shares our commitment to advance critically needed innovations in womens health.